skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Laura

USA

+34 year(s) experience

Laura Runkel |Pharma Intelligence|
Associate Director Laura Runkel supports clinical trial intelligence for the autoimmune/inflammation, CNS and ophthalmology therapeutic areas. She tracks drug development and related clinical trials to prepare analytical reports and provide clients with direct insights.
In addition to supporting content for the broad areas of autoimmune/inflammation, CNS, Ophthalmology diseases, Laura's specialities include biosimilar programs for autoimmune and inflammatory indications and drug programs for asthma, COPD, lupus, rheumatoid arthritis, inflammatory bowel disease, and psoriasis.  

Prior to joining Citeline in 2006, Laura gained research experience in liver pathologies (HBV, fibrosis), and cytokine/interferon pathologies/function, both of which have deepened the insights she can provide to our pharma clients interested in these areas. 

Analyst Articles

Articles by Laura

  • Trialtrove: 医療用医薬品の臨床試験情報データベース

    Geographic Trials Trends: Digging Beneath the Surface

    Geographic Trials Trends: Digging Beneath the Surface

    The geographic scope of industry sponsored clinical trial activities has gone global. Successful programs require putting all the pieces together to ensure efficient enrollment of the target patients at high quality facilities to reliably execute detailed study protocols.  Myriad differences between countries, including disease epidemiology, standard of care options, and logistical factors around medical facilities and practices, create challenges to making the right geographic choices.

    Topic Clinical trials

  • Trialtrove: 医療用医薬品の臨床試験情報データベース

    Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

    Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

    Explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.